ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Alprazolam: Drug information

Alprazolam: Drug information
(For additional information see "Alprazolam: Patient drug information" and see "Alprazolam: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Risks from concomitant use with opioids:

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

Abuse, misuse, and addiction:

The use of benzodiazepines, including alprazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing alprazolam and throughout treatment, assess each patient's risk for abuse, misuse, and addiction.

Dependence and withdrawal reactions:

The continued use of benzodiazepines, including alprazolam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of alprazolam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam or reduce the dosage.

Brand Names: US
  • ALPRAZolam Intensol;
  • ALPRAZolam XR;
  • Xanax;
  • Xanax XR
Brand Names: Canada
  • ALPRAZolam TS;
  • APO-Alpraz;
  • APO-Alpraz TS;
  • JAMP-Alprazolam [DSC];
  • PRO-Alprazolam;
  • TEVA-Alprazolam;
  • Xanax;
  • Xanax TS
Pharmacologic Category
  • Benzodiazepine
Dosing: Adult

Dosage guidance:

Safety: Reduce dose or avoid use in patients receiving opioids or with significant chronic disease (eg, respiratory compromise). Avoid use in patients with a history of substance use, misuse of medications, or depression (Ref).

Anxiety

Anxiety:

Anxiety disorders (adjunctive therapy or monotherapy) (alternative agent):

Note: Generally used short term for symptom relief until preferred therapy (eg, serotonin reuptake inhibitor) is effective (eg, 4 to 6 weeks, followed by tapering). Long-term, low-dose therapy (eg, 2 mg/day) may be considered in select patients when other treatments are ineffective or poorly tolerated (Ref). Use with caution in patients with posttraumatic stress disorder; benzodiazepines may worsen symptoms (Ref).

Immediate release: Oral: Initial: 0.25 mg 3 to 4 times daily; may increase dose based on response and tolerability in increments ≤1 mg/day at intervals ≥3 days up to a usual dose of 2 to 6 mg/day in 3 to 4 divided doses. Some patients may require up to 8 mg/day for optimal response; manufacturer's labeling maximum: 10 mg/day. With doses >4 mg/day, increase more gradually to minimize adverse effects; periodically reassess and consider dosage reduction (Ref).

Extended release (panic disorder labeled use): Oral: Initial: 0.5 to 1 mg once daily; may increase dose based on response and tolerability in increments ≤1 mg/day at intervals ≥3 days up to a usual dose of 2 to 6 mg/day. Some patients may require up to 8 mg/day for optimal response; manufacturer's labeling maximum: 10 mg/day. With doses >4 mg/day, increase more gradually to minimize adverse effects; periodically reassess and consider dosage reduction. Administration in 2 divided doses may be considered to maximize efficacy (Ref).

Procedural anxiety (premedication) (off-label use):

Immediate release: Oral, Sublingual: 0.5 mg 30 to 90 minutes before procedure; if needed due to incomplete response and/or duration of procedure, may repeat the dose (usually at 50% of the initial dose) after 30 to 60 minutes (Ref).

Vertigo, acute episodes

Vertigo, acute episodes (alternative agent) (off-label use):

Note: Reserve use for symptomatic relief of episodes lasting several hours to days (maximum duration: 3 days); chronic use may impede adaptation and recovery (Ref).

Immediate release: Oral: Initial: 0.5 mg every 8 hours as needed for up to 48 to 72 hours (Ref).

Dosing conversions: Immediate release to extended release: ER tablet may be substituted for the IR tablet on a mg-per-mg basis, administering the ER tablet once daily. Administration of the ER formulation in 2 divided doses may be considered to maximize efficacy (Ref).

Discontinuation of therapy: Unless safety concerns require a more rapid withdrawal, gradually taper to detect reemerging symptoms and minimize rebound and withdrawal symptoms in patients receiving therapy ≥4 weeks or as appropriate based on patient-specific factors (Ref).

Low or moderate dose, no concerns for benzodiazepine use disorder : Taper total daily dose by 20% to 25% every week based on response and tolerability (taper increments will be limited by available dosage forms) (Ref).

Extended or high-dose therapy, or suspected benzodiazepine use disorder: Taper total daily dose by approximately 25% every 1 to 2 weeks based on response, tolerability, and individual patient factors (taper increments will be limited by available dosage forms) (Ref). Reduce dose more rapidly in the beginning and slow the dose reduction as the taper progresses because earlier stages of withdrawal are easier to tolerate (Ref). The optimal duration and taper increment will vary; up to 6 months may be necessary for some patients on higher doses, and a taper rate of 50% every week may be tolerated in some patients (Ref). For benzodiazepines with half-lives significantly <24 hours, including alprazolam, consider substituting an equivalent dose of a long-acting benzodiazepine to allow for a more gradual reduction in drug serum concentrations (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

CrCl ≥10 mL/minute: No dosage adjustment necessary (Ref).

CrCl <10 mL/minute: No dosage adjustment necessary; use with caution as enhanced pharmacodynamic effects (eg, psychomotor and memory impairment) may be observed in patients with end-stage kidney disease (Ref).

Hemodialysis, intermittent (thrice weekly): Significant removal by hemodialysis is unlikely (moderately protein bound; moderate Vd) (Ref):

No dosage adjustment necessary (Ref). Use with caution as enhanced pharmacodynamic effects (eg, psychomotor and memory impairment) may be observed (Ref).

Peritoneal dialysis: Significant removal by hemodialysis is unlikely (moderately protein bound; moderate Vd) (Ref):

Initial: Consider administering 50% to 75% of the usual indication-specific recommended dose; in one pharmacokinetic study patients on peritoneal dialysis exhibited a higher free fraction and AUC compared to patients with normal kidney function and hemodialysis patients (Ref). Additionally, enhanced pharmacodynamic effects (eg, psychomotor and memory impairment) may be observed (Ref).

CRRT: Drug clearance may be dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Close monitoring of response and adverse reactions (eg, sedation, respiratory depression) due to drug accumulation is important.

No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Drug clearance may be dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions (eg, sedation, respiratory depression) due to drug accumulation is important.

No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

Advanced liver disease:

IR tablet, oral concentrate, orally disintegrating tablet: 0.25 mg 2 to 3 times daily.

Extended release: 0.5 mg once daily

Dosing: Older Adult

Note: Avoid use; may be appropriate for severe generalized anxiety disorder (Ref).

Immediate release: Oral: Use lower initial doses of 0.25 mg 2 to 3 times daily and titrate slowly; refer to adult dosing.

Extended release: Oral: Use lower initial doses of 0.5 mg once daily and titrate slowly; refer to adult dosing.

Dosing conversions: Refer to adult dosing.

Discontinuation of therapy: Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Alprazolam: Pediatric drug information")

Dosage guidance:

Dosing: All pediatric dosing for immediate-release formulations unless otherwise specified. Titrate dose to effect; use lowest effective dose.

Anxiety

Anxiety:

Children ≥7 years and Adolescents <18 years: Limited data available: Oral: Initial: 0.005 to 0.02 mg/kg/dose 3 times daily; in trials, doses were rounded to nearest available tablet size (lowest available dose is 0.125 mg [1/2 of 0.25 mg tablet]). May titrate at 2- to 3-day intervals in 0.125 to 0.25 mg/dose increments up to a maximum 0.06 mg/kg/day or 4 mg/day, whichever is less (Ref).

Dosing based on 2 small open-label trials (n=13, n=17) in patients diagnosed with situational anxiety, overanxious disorder, or avoidant disorder; the reported ranges were 0.375 to 3 mg/day in one trial (Ref) and in the other trial, 0.5 to 3.5 mg/day with a mean of 1.6 mg/day was reported and based on clinical global ratings, alprazolam appeared to be better than placebo; however, this difference was not statistically significant (Ref).

Discontinuation of therapy: Abrupt discontinuation should be avoided. Unless safety concerns require a more rapid withdrawal, gradually taper to detect reemerging symptoms and minimize rebound and withdrawal symptoms in patients receiving therapy ≥4 weeks or as appropriate based on patient-specific factors (Ref). Daily dose must be gradually decreased no more frequently than every 3 days; however, some patients may require a slower reduction. If withdrawal symptoms occur, resume previous dose and discontinue on a less rapid schedule.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

Pediatric-specific recommendations are not available; in adults, lower doses are suggested if advanced liver disease present.

Adverse Reactions (Significant): Considerations
Anterograde amnesia

Anterograde amnesia: Benzodiazepines can impair explicit memory and produce short-term anterograde amnesia (ie, memory of information or events after drug administration). Retrograde amnesia (ie, events or information prior to drug administration) is unaffected. However, the magnitude of the amnesic effect from benzodiazepines differs among the various agents, depending on their pharmacokinetic/pharmacodynamic properties, route of administration, and dose. Anterograde amnesia is associated with higher doses, IV administration, and benzodiazepines with faster absorption and higher potency (Ref).

Mechanism: Dose-related. Benzodiazepines, including alprazolam, bind to the gamma-aminobutyric acid (GABA)-A receptor, subsequently increasing the frequency of chloride channel opening and producing GABA’s inhibitory effect throughout the CNS. The GABA-A receptor complex is composed of 5 subunits, each with multiple isoforms. Each receptor complex contains a benzodiazepine-binding site, which is classified into several types, based on the alpha subunit isoforms and clinical effects related to each type. The BZ1 receptor type, containing the alfa 1 subunit isoform, is highly concentrated in the cortex, thalamus, and cerebellum, and is responsible for benzodiazepine-associated anterograde amnesia (Ref).

Onset: Rapid; during chronic benzodiazepine administration, tolerance appears to develop, and memory impairment is limited to a window of 90 minutes following each dose (Ref).

Risk factors:

• Specific benzodiazepine: Benzodiazepines, such as alprazolam, with a high affinity for the benzodiazepine-receptor site, are associated with a higher propensity for amnesic effects (Ref)

• Higher doses (Ref)

CNS effects

CNS effects: Alprazolam can cause drowsiness, fatigue, decreased alertness, and confusion. In addition, alprazolam has been shown to cause ataxia and psychomotor impairment. Tolerance usually develops to its sedative and psychomotor effects (Ref). Benzodiazepines, in general, are associated with an increased risk of motor vehicle accidents and falls (particularly in older adults) (Ref).

Mechanism: Dose-related (Ref); benzodiazepines, including alprazolam, bind to the gamma-aminobutyric acid (GABA)-A receptor, subsequently increasing the frequency of chloride channel opening and producing GABA’s inhibitory effect throughout the CNS. Benzodiazepine-associated sedation are mediated by the alpha 1-containing GABA-A receptors (Ref).

Onset: Sedation (mean onset): 40 minutes following a single 1 mg oral dose of immediate release alprazolam (Ref).

Risk factors:

Sedating effects:

• Older adults (benzodiazepines in general) (Ref). Note: Conflicting data exists for alprazolam specifically (Ref)

• Higher doses (Ref)

• Titrating the initial dose too rapidly (gradual titration and dividing the dosing frequently, if using the immediate release formulation, is preferred) (Ref)

• Immediate release formulation is associated with a higher risk for sedation compared to extended release (due to lower absorption rate of the extended release resulting in peak plasma concentrations that are half those of immediate release) (Ref)

• Concomitant use of other CNS depressants (Ref)

Paradoxical reactions

Paradoxical reactions, sometimes referred to as disinhibitory reactions or behavioral disinhibition, have been reported in children, adults, and older adults with benzodiazepine use, particularly in those with risk factors. Reactions are relatively uncommon and have been characterized in a number of ways, including increased talkativeness, excitement, restlessness, hyperactivity, sleep disturbances, hostility, rage, agitation, and/or aggressive behavior (Ref). In children, paradoxical reactions to benzodiazepines, particularly midazolam, have been most commonly described as agitation, restlessness, inconsolable crying, screaming, disorientation, and/or excitement (Ref). Of note, alprazolam has been frequently associated with behavioral aggression in adults (Ref).

Mechanism: Dose-related (potentially, although may also be idiosyncratic); exact mechanism is unclear due to limited evidence (Ref). One hypothesis has suggested that increased GABAergic activity in the brain from benzodiazepines causes a decrease in the restraining influence of the frontal cortex, thereby causing excitement, hostility, and rage. An additional proposed mechanism is that benzodiazepines can reduce serotonergic neurotransmission, subsequently causing aggressive behavior. Another mechanism is that in select patients with genetic variations in GABA-A receptors, there is decreased GABA transmission with benzodiazepines which results in neuronal overexcitation manifested clinically as a paradoxical reaction (Ref).

Risk factors:

Benzodiazepines in general:

Age-related (extremes of age):

• Children (Ref)

• Older adults (Ref)

Disease- or condition-related:

• Past history of aggressive behavior or violence (Ref)

• Alcoholism or history of alcohol use (Ref) or social use of alcohol (on risk of aggressive behavior with alprazolam, specifically) (Ref)

• Psychiatric or personality disorders, including affective disorder (Ref)

• Dementia (Ref).

Patient-related:

• Genetic predisposition (potential risk factor) (ie, variability in the density of the GABA-benzodiazepine receptors throughout the brain, a persistence of a juvenile pattern of benzodiazepine response in adulthood, or multiple allelic forms of the receptors with varying affinities for benzodiazepines have all been suggested as potentially playing a role) (Ref)

Other potential risk factors: Note: No established risk factors since evidence is limited (Ref)

• Higher doses (likely a risk, but not firmly established) (Ref)

• Parenteral benzodiazepine administration (potential risk) (Ref).

• Specific benzodiazepines (potential risk): Benzodiazepines with a higher potency (eg, alprazolam, clonazepam) and/or a short half-life (eg, alprazolam) are believed to carry an increased risk; however, it has also been suggested that there is no difference in risk among the various benzodiazepines (Ref)

Withdrawal syndrome

Withdrawal syndrome: Therapeutic use of benzodiazepines, including alprazolam, is associated with a withdrawal syndrome in children and adults, particularly following abrupt or overly rapid discontinuation following regular use. Benzodiazepine-associated withdrawal symptoms can include new withdrawal symptoms or rebound symptoms, both of which are typically transient, short-lasting, and reversible. A persistent post-withdrawal disorder, which can be long-lasting, severe, and potentially irreversible, has also been described. In general, withdrawal symptoms are typically mild and characterized as anxiety, panic attacks, restlessness, insomnia and other sleep disturbances, irritability, poor concentration, confusion, nausea/vomiting, weight loss, tremor, diaphoresis, tachycardia, and muscle pain/stiffness. Severe symptoms such as seizure and psychosis may also rarely occur following abrupt discontinuation. Severe withdrawal may be fatal. Data are limited on persistent post-withdrawal disorders, but cognitive impairment; depression; anxiety; sensory disturbances (eg, tinnitus, paresthesia, skin sensations); motor disturbances (eg, muscle pain, weakness, spasms); and GI disturbances have been described (Ref). For alprazolam specifically, there are also rare case reports of new-onset withdrawal catatonia occurring after abrupt withdrawal of chronic therapy (Ref). Severity, onset, and duration of any benzodiazepine withdrawal syndrome varies based on several factors, such as specific benzodiazepine administered (and its half-life), dose, and duration of use. However, in general, new withdrawal symptoms typically resolve within 2 to 4 weeks and rebound symptoms may last 3 weeks, but persistent post-withdrawal symptoms may last >6 weeks and take 6 to 12 months to completely resolve, and in some cases, persist for years (Ref).

Mechanism: Withdrawal; exact mechanisms are complex and unclear, but chronic exposure to benzodiazepines alters GABAergic neurotransmission (up/down regulation of gamma-aminobutyric acid [GABA]-A receptor subunits) and rapid or abrupt withdrawal results in underactivity of inhibitory GABA functions subsequently increasing excitatory nervous activity and likely contributing to symptoms associated with withdrawal (Ref). A role of glutamate receptors, including N-methyl-D aspartate (NMDA)-, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-receptors, and metabotropic glutamate (mGlu) receptors, has also been suggested. In mice and rat studies, antagonists for glutamate receptors have shown the ability to potently suppress the withdrawal signs caused by chronic benzodiazepine administration (Ref).

Onset: Varied; onset of symptoms usually occurs within the first day following abrupt withdrawal of short- acting or intermediate-acting benzodiazepines (such as alprazolam and lorazepam, respectively). Long-acting benzodiazepines (eg, diazepam, flurazepam) are usually associated with an initial onset of withdrawal symptoms 5 days following abrupt discontinuation (Ref). Alprazolam may produce physical dependence after durations of only a few weeks and in doses as small as 0.75 to 1 mg/day (Ref). In general, persistent post-withdrawal disorder associated with psychotropic medications (eg, benzodiazepines) have an onset ranging from 24 hours to 6 weeks following a decrease, discontinuation, or switch (Ref).

Risk factors:

Benzodiazepines in general:

• Abrupt discontinuation (rather than gradual dosage reduction) of a benzodiazepine used long-term (Ref)

• Higher doses (Ref)

• Chronic dosing (ie, intermittent dosing may reduce the risk of withdrawal symptoms) (Ref)

• Long treatment durations (Ref)

• Withdrawal-associated seizure: Predisposed patients (eg, brain damage, alcohol abuse, history of seizure, or those taking medications that lower the seizure threshold) (Ref)

Alprazolam specifically:

• History of substance use disorder, including alcohol use disorder (Ref)

• Specific benzodiazepine: High-potency benzodiazepines with short and intermediate half-lives generally have a higher risk for rebound, withdrawal reactions, and dependence compared to long-acting agents. Alprazolam is a high potency benzodiazepine with a short half-life and may produce more dependency and withdrawal than many other benzodiazepines. Benzodiazepines with a relatively longer half-life (usually reported at >24 hours in adults), such as clonazepam, are usually associated with fewer (and potentially less severe) rebound and withdrawal symptoms, particularly if tapered appropriately (Ref).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults. [IR = Immediate release, ER = Extended release]

>10%:

Dermatologic: Skin rash (IR: 11%; ER: <1%)

Endocrine & metabolic: Decreased libido (6% to 14%), weight gain (IR: 27%; ER: 5%), weight loss (IR: 23%)

Gastrointestinal: Constipation (IR: 26%; ER: 8%), decreased appetite (IR: 28%), increased appetite (IR: 33%; ER: 7%), xerostomia (IR: 15%)

Genitourinary: Difficulty in micturition (IR: 12%; ER: ≥1%)

Nervous system: Ataxia (IR: 40%; ER: 7% to 9%) (table 1), cognitive dysfunction (IR: 29%; ER: Bradyphrenia: <1%), depression (ER: 12%; depressed mood: 1%), dizziness (IR: 2% to 21%; ER: ≥1%), drowsiness (IR: 41% to 77%; ER: 23%) (table 2), dysarthria (IR: 23%; ER: 11%), fatigue (IR: 49%; ER: 14%) (table 3), irritability (IR: 33%; ER: ≥1%), memory impairment (IR: 33%; ER: 15%), sedated state (ER: 45%)

Alprazolam: Adverse Reaction: Ataxia

Drug (Alprazolam)

Placebo

Dosage Form

Indication

Number of Patients (Alprazolam)

Number of Patients (Placebo)

Comments

40%

18%

Immediate-release tablets

Panic disorder

1,388

1,231

Described as "impaired coordination"

9%

1%

Extended-release tablets

Panic disorder

531

349

Described as "coordination abnormal"

7%

3%

Extended-release tablets

Panic disorder

531

349

N/A

Alprazolam: Adverse Reaction: Drowsiness

Drug (Alprazolam)

Placebo

Dosage Form

Indication

Number of Patients (Alprazolam)

Number of Patients (Placebo)

41%

22%

Immediate-release tablets

Generalized anxiety

565

505

77%

43%

Immediate-release tablets

Panic disorder

1,388

1,231

23%

6%

Extended-release tablets

Panic disorder

531

349

Alprazolam: Adverse Reaction: Fatigue

Drug (Alprazolam)

Placebo

Dosage Form

Indication

Number of Patients (Alprazolam)

Number of Patients (Placebo)

49%

42%

Immediate-release tablets

Panic disorder

1,388

1,231

14%

9%

Extended-release tablets

Panic disorder

531

349

1% to 10%:

Cardiovascular: Chest pain (ER: ≥1%), hypotension (IR: 5%; ER: <1%), palpitations (ER: ≥1%)

Dermatologic: Allergic skin reaction (IR: ≤4%), dermatitis (IR: ≤4%), diaphoresis (ER: ≥1%)

Endocrine & metabolic: Change in libido (IR: 7%), increased libido (IR: 8%; ER: ≥1%), menstrual disease (IR: 10%)

Gastrointestinal: Abdominal pain (ER: ≥1%), anorexia (ER: 2%), diarrhea (ER: ≥1%), dyspepsia (ER: ≥1%), nausea (ER: 6%), sialorrhea (IR: 4% to 6%; ER: ≥1%), vomiting (ER: ≥1%)

Genitourinary: Dysmenorrhea (ER: 4%), sexual disorder (IR: 7%; ER: 2%), urinary incontinence (≤2%)

Nervous system: Agitation (ER: ≥1%), akathisia (IR: 2%), asthenia (ER: ≥1%), balance impairment (ER: 3%), confusion (IR: 10%; ER: 2%) (table 4), decreased mental acuity (ER: 7%), depersonalization (ER: ≥1%), derealization (≥1%), disinhibition (IR: 3%), disorientation (ER: 2%), disturbance in attention (ER: 3%), feeling hot (≤1%), headache (ER: ≥1%), hypersomnia (ER: 1%), hypoesthesia (ER: 1%), insomnia (ER: ≥1%), lethargy (ER: 2%), malaise (ER: ≥1%), nervousness (ER: ≥1%), nightmares (ER: ≥1%), restlessness (ER: ≥1%), talkativeness (≤2%), tremor (ER: ≥1%), vertigo (ER: ≥1%)

Alprazolam: Adverse Reaction: Confusion

Drug (Alprazolam)

Placebo

Dosage Form

Indication

Number of Patients (Alprazolam)

Number of Patients (Placebo)

10%

8%

Immediate-release tablets

Panic disorder

1,388

1,231

2%

1%

Extended-release tablets

Panic disorder

531

349

Neuromuscular & skeletal: Arthralgia (ER: 2%), back pain (ER: ≥1%), dyskinesia (ER: 2%), limb pain (ER: 1%), muscle cramps (ER: ≥1%), muscle twitching (ER: ≥1%), myalgia (ER: 2%)

Ophthalmic: Blurred vision (ER: ≥1%)

Respiratory: Dyspnea (ER: 2%), hyperventilation (ER: ≥1%), nasal congestion (ER: ≥1%)

<1%:

Cardiovascular: Chest tightness (ER), edema (ER), sinus tachycardia (ER), syncope (ER)

Dermatologic: Cold and clammy skin (ER), urticaria (ER)

Endocrine & metabolic: Increased thirst (ER)

Gastrointestinal: Dysgeusia (IR), dysphagia (ER)

Genitourinary: Urinary frequency (ER)

Hepatic: Increased serum bilirubin (IR)

Nervous system: Abnormal dreams (ER), aggressive behavior (ER), amnesia (ER), apathy (ER), choking sensation (ER), clumsiness (ER), emotional lability (ER), euphoria (ER), falling (ER), hallucination, hangover effect (ER), homicidal ideation (ER), hypomania, hypotonia (ER), impaired consciousness (ER), impulse control disorder (ER), increased energy (ER), intoxicated feeling (ER), jitteriness (ER), mania, outbursts of anger (ER), paraplegia (ER), psychomotor impairment (ER), relaxation (ER), rigors (ER), seizure, sensation of cold (ER), sleep talking (ER), stupor (ER), suicidal ideation (ER), voice disorder (ER)

Ophthalmic: Diplopia (IR), mydriasis (ER), photophobia (ER)

Otic: Otalgia (ER), tinnitus (ER)

Respiratory: Epistaxis (ER), rhinorrhea (ER), sleep apnea (ER)

Miscellaneous: Fever (ER)

Frequency not defined: Nervous system: Paresthesia

Postmarketing:

Cardiovascular: Peripheral edema

Dermatologic: Skin photosensitivity (Kanwar 1990), Stevens-Johnson syndrome

Endocrine & metabolic: Amenorrhea (Petrić 2011; Shioiri 1996), galactorrhea not associated with childbirth (Petrić 2011; Shioiri 1996), gynecomastia, hyperprolactinemia (Shioiri 1996)

Hepatic: Hepatic failure, hepatitis (Judd 1986), increased liver enzymes (Judd 1986), jaundice (Judd 1986)

Hypersensitivity: Angioedema

Nervous system: Anterograde amnesia (Curran 1994), drug abuse (Juergens 1988; Sheehan 1991), drug dependence (Juergens 1988), hostility (Rapaport 1985), withdrawal syndrome (including catatonia, rebound anxiety, and status epilepticus) (Mellman 1986; Oldham 2016; Vicente Ferreira Naves 2018)

Miscellaneous: Paradoxical reaction (including muscle spasticity, paradoxical central nervous system stimulation, and sleep disturbance) (Kirkpatrick 2016)

Contraindications

Hypersensitivity to alprazolam, any component of the formulation, or other benzodiazepines (cross-sensitivity with other benzodiazepines may exist); concurrent therapy with strong cytochrome P-450 3A (CYP3A) inhibitors (eg, itraconazole, ketoconazole), except ritonavir; acute narrow angle glaucoma.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Canadian labeling: Additional contraindications (not in US labeling): Myasthenia gravis; severe hepatic insufficiency; severe respiratory insufficiency; sleep apnea.

Warnings/Precautions

Concerns related to adverse effects:

• Sleep-related activities: Hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep have been noted with benzodiazepines (Dolder 2008).

Disease-related concerns:

• Depression: Avoid use in patients with depression because of concerns about worsening mood symptoms, particularly if suicidal risk may be present, except for acute or emergency situations (eg, acute agitation, status epilepticus) (Craske 2022).

• Hepatic impairment: Use with caution in patients with hepatic impairment.

• Renal impairment: Use with caution in patients with renal impairment or predisposition to urate nephropathy; has weak uricosuric properties.

• Respiratory disease: Reduce dose or avoid use in patients with respiratory disease, including chronic obstructive pulmonary disease or sleep apnea. Benzodiazepines may cause significant respiratory depression.

Concurrent drug therapy issues:

• Flumazenil: Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.

Special populations:

• Debilitated patients: Use with caution in debilitated patients; use lower starting dose.

• Older adult patients: Older adults may be at an increased risk of death with use; risk has been found highest within the first 4 months of use in elderly dementia patients (Jennum 2015; Saarelainen 2018).

• Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury (Nelson 1999).

• Obese patients: Use with caution in obese patients; may have prolonged action when discontinued.

• Smokers: Cigarette smoking may decrease alprazolam concentrations up to 50%.

Other warnings/precautions:

• Abuse, misuse, and substance use disorder: Counsel patients at increased risk on proper use and monitoring for signs and symptoms of abuse, misuse, and substance use disorder. Institute early treatment or refer patients in whom substance use disorder is suspected. Limit dosages and durations to the minimum required.

• Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.

• Breakthrough anxiety: At the end of dosing interval, breakthrough anxiety may occur.

• Tolerance: Alprazolam has a short half-life for a benzodiazepine and the duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance does not develop to the anxiolytic effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Concentrate, Oral:

ALPRAZolam Intensol: 1 mg/mL (30 mL) [unflavored flavor]

Tablet, Oral:

Xanax: 0.25 mg [scored]

Xanax: 0.5 mg [scored; contains fd&c yellow #6 (sunset yellow)]

Xanax: 1 mg [scored; contains fd&c blue #2 (indigotine,indigo carmine)]

Xanax: 2 mg [scored]

Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg

Tablet Disintegrating, Oral:

Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg

Tablet Extended Release 24 Hour, Oral:

ALPRAZolam XR: 0.5 mg

ALPRAZolam XR: 1 mg [contains quinoline yellow (d&c yellow #10)]

ALPRAZolam XR: 2 mg [contains fd&c blue #2 (indigotine,indigo carmine)]

ALPRAZolam XR: 3 mg [contains fd&c blue #2 (indigotine,indigo carmine), quinoline yellow (d&c yellow #10)]

Xanax XR: 0.5 mg

Xanax XR: 1 mg [contains quinoline yellow (d&c yellow #10)]

Xanax XR: 2 mg [contains fd&c blue #2 (indigotine,indigo carmine)]

Xanax XR: 3 mg [contains fd&c blue #2 (indigotine,indigo carmine), quinoline yellow (d&c yellow #10)]

Generic: 0.5 mg, 1 mg, 2 mg, 3 mg

Generic Equivalent Available: US

May be product dependent

Pricing: US

Concentrate (ALPRAZolam Intensol Oral)

1 mg/mL (per mL): $3.66

Tablet, 24-hour (ALPRAZolam ER Oral)

0.5 mg (per each): $2.15 - $2.26

1 mg (per each): $2.67 - $2.81

2 mg (per each): $3.55 - $3.73

3 mg (per each): $5.32 - $5.59

Tablet, 24-hour (Xanax XR Oral)

0.5 mg (per each): $12.00

1 mg (per each): $14.93

2 mg (per each): $19.82

3 mg (per each): $29.72

Tablet, orally-disintegrating (ALPRAZolam Oral)

0.25 mg (per each): $1.52 - $2.18

0.5 mg (per each): $1.89 - $2.72

1 mg (per each): $2.52 - $3.63

2 mg (per each): $4.29 - $6.17

Tablets (ALPRAZolam Oral)

0.25 mg (per each): $0.60 - $0.70

0.5 mg (per each): $0.76 - $0.93

1 mg (per each): $0.96 - $1.16

2 mg (per each): $1.69 - $1.96

Tablets (Xanax Oral)

0.25 mg (per each): $6.23

0.5 mg (per each): $7.76

1 mg (per each): $10.35

2 mg (per each): $17.60

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Xanax: 0.25 mg [contains corn starch, docusate sodium/sodium benzoate]

Xanax: 0.5 mg [contains corn starch, docusate sodium/sodium benzoate, fd&c yellow #5 (tartrazine)aluminum lake, fd&c yellow #6(sunset yellow)alumin lake, quinoline (d&c yellow #10) aluminum lake]

Xanax: 1 mg [contains corn starch, docusate sodium/sodium benzoate, fd&c blue #1 (brill blue) aluminum lake, fd&c blue #2 (indigo carm) aluminum lake]

Xanax TS: 2 mg [contains corn starch, docusate sodium/sodium benzoate]

Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg

Controlled Substance

C-IV

Administration: Adult

Oral:

IR preparations: May be administered sublingually if oral administration is not possible; absorption and onset of effect are comparable to oral administration (Ref)

ER tablet: Should be taken once daily in the morning; do not crush, break, or chew.

Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation.

Oral concentrate: Use only the provided calibrated dropper to withdraw the prescribed dose. Mix the dose with ≥30 mL of juice or other liquid or semi-solid foods (eg, applesauce, pudding). The prepared mixture should be administered immediately.

Orally disintegrating tablets: Using dry hands, place tablet on top of tongue and allow to disintegrate. Administration with water is not necessary.

Administration: Pediatric

Oral:

Immediate-release tablet: In adults, may be administered sublingually if oral administration is not possible; absorption and onset of effect is comparable to oral administration (Ref).

Oral concentrate: Use only the provided calibrated dropper to withdraw the prescribed dose. Mix the dose with ≥30 mL of juice or other liquid or semi-solid foods (eg, applesauce, pudding). The prepared mixture should be administered immediately.

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Xanax: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018276s059lbl.pdf#page=22

Xanax XR: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021434s022lbl.pdf#page=23

Use: Labeled Indications

Anxiety disorders: Treatment of generalized anxiety disorder, short-term anxiety, and anxiety associated with depression (IR tablet, oral concentrate, orally disintegrating tablets); treatment of panic disorder with or without agoraphobia (IR tablet, ER tablet, oral concentrate, orally disintegrating tablets).

Use: Off-Label: Adult

Vertigo, acute episodes

Medication Safety Issues
Sound-alike/look-alike issues:

ALPRAZolam may be confused with alprostadil, clonazePAM, LORazepam, triazolam

Xanax may be confused with Fanapt, Lanoxin, Tenex, Tylox, Xopenex, Zantac, ZyrTEC

Older Adult: High-Risk Medication:

Beers Criteria: Alprazolam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to risk of abuse, misuse, physical dependence, and addiction. In addition, older adults have increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use. However, benzodiazepines may be appropriate in the elderly when used for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine or ethanol withdrawal, severe generalized anxiety disorder, or periprocedural anesthesia (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

Substrate of CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP3A4 (weak)

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy

Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. Risk C: Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine. Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined. Risk D: Consider therapy modification

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy

CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). Risk C: Monitor therapy

CYP3A4 Inducers (Moderate): May decrease the serum concentration of ALPRAZolam. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of ALPRAZolam. Risk C: Monitor therapy

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of ALPRAZolam. Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy). Risk D: Consider therapy modification

CYP3A4 Inhibitors (Strong): May increase the serum concentration of ALPRAZolam. Risk X: Avoid combination

CYP3A4 Inhibitors (Weak): May increase the serum concentration of ALPRAZolam. Risk C: Monitor therapy

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Delavirdine: May increase the serum concentration of ALPRAZolam. Risk X: Avoid combination

DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider therapy modification

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. Risk C: Monitor therapy

Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. Risk C: Monitor therapy

DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification

Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor therapy

Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor therapy

Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk X: Avoid combination

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. Risk C: Monitor therapy

Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. Risk C: Monitor therapy

Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor therapy

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification

Ilaprazole: May increase the serum concentration of Benzodiazepines. Risk C: Monitor therapy

Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant. Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors. Risk D: Consider therapy modification

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide. Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day. Risk D: Consider therapy modification

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Melatonin: May enhance the sedative effect of Benzodiazepines. Risk C: Monitor therapy

Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone. Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution. Risk D: Consider therapy modification

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy

Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor therapy

Nabilone: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Nefazodone: May increase the serum concentration of ALPRAZolam. Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy). Risk D: Consider therapy modification

NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. Risk C: Monitor therapy

Nirmatrelvir and Ritonavir: May increase the serum concentration of ALPRAZolam. Management: Reduce the alprazolam dose by 50% when a patient is started on nirmatrelvir/ritonavir and alprazolam together, or when nirmatrelvir/ritonavir is initiated in a patient already treated with alprazolam. Risk D: Consider therapy modification

Nirogacestat: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk X: Avoid combination

OLANZapine: Benzodiazepines may enhance the adverse/toxic effect of OLANZapine. Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended. Risk C: Monitor therapy

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of ALPRAZolam. Risk C: Monitor therapy

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of ALPRAZolam. Risk C: Monitor therapy

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Oxybate Salt Products: Benzodiazepines may enhance the CNS depressant effect of Oxybate Salt Products. Risk X: Avoid combination

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Pacritinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk X: Avoid combination

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. Risk X: Avoid combination

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Ritlecitinib: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor therapy

Ritonavir: May increase the serum concentration of ALPRAZolam. Specifically, this occurs with ritonavir initiation/short-term use. Management: Reduce alprazolam dose by 50% when ritonavir and alprazolam are initiated together, or when ritonavir is initiated in a patient already treated with alprazolam. No alprazolam dose reduction required in patients taking ritonavir for more than 10 to 14 days Risk D: Consider therapy modification

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. Risk C: Monitor therapy

Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). Risk C: Monitor therapy

Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound). Management: Reduce the dose of protein bound sirolimus to 56 mg/m2 when used concomitantly with a weak CYP3A4 inhibitor. Risk D: Consider therapy modification

Spironolactone: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor therapy

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). Risk C: Monitor therapy

Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor therapy

Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor therapy

Teduglutide: May increase the serum concentration of Benzodiazepines. Risk C: Monitor therapy

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines. Risk C: Monitor therapy

Treosulfan: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk X: Avoid combination

Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. Risk C: Monitor therapy

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Trofinetide: May increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor therapy

Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant. Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg. Risk D: Consider therapy modification

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Yohimbine: May diminish the therapeutic effect of Antianxiety Agents. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider therapy modification

Food Interactions

The Cmax of the extended release formulation is increased by 25% when a high-fat meal is given 2 hours before dosing. Tmax is decreased 33% when food is given immediately prior to dose and increased by 33% when food is given ≥1 hour after dose. Management: Administer without regard to food.

Reproductive Considerations

Amenorrhea and galactorrhea were observed in a patient following self-medication with high doses of alprazolam (alprazolam extended release 3 mg and alprazolam 5 to 6 mg daily for several months). Following a tapered withdrawal of alprazolam, prolactin levels returned to normal, regular menstrual cycles resumed, and galactorrhea resolved (Petric 2011).

Therapy for anxiety should be individualized (BAP [McAllister-Williams 2017]); avoid the use of benzodiazepines for the treatment of anxiety disorders in patients planning to become pregnant (Larsen 2015).

Alprazolam can be detected in seminal fluid; however, alterations of the seminal profile (eg, sperm concentration, motility) were not observed in 4 patients evaluated (Mazzilli 2021).

Pregnancy Considerations

Alprazolam and its metabolites cross the human placenta (García-Algar 2007).

In utero exposure to benzodiazepines has the potential to cause harm to the fetus. Teratogenic effects have been observed in some studies; however, a clear association has not been reported and additional data are needed (Bellantuono 2013; Freeman 2018; Grigoriadis 2019; Noh 2022; Szpunar 2022; Tinker 2019; Wikner 2007). Exposure to a benzodiazepine late in pregnancy may cause neonatal sedation (hypotonia, lethargy, and respiratory depression) and/or symptoms of neonatal withdrawal (feeding difficulties, hyperreflexia, inconsolable crying, irritability, restlessness, and tremors). Data related to long-term effects on neurodevelopment are inconclusive (Chen 2022; Radojčić 2017; Sundbakk 2022; Wang 2022). Newborns exposed to alprazolam in utero should be monitored for feeding problems, respiratory depression, sedation, and withdrawal.

Therapy for anxiety during pregnancy should be individualized. Untreated or inadequately treated psychiatric illness may lead to poor adherence to prenatal care and adverse pregnancy outcomes (ACOG 2008). Benzodiazepines are not preferred when pharmacologic treatment for anxiety disorders is needed during pregnancy (BAP [McAllister-Williams 2017]; Larsen 2015) and when a benzodiazepine is needed, the use of alprazolam is not preferred. If possible, avoid scheduled doses of benzodiazepines in the month prior to delivery to reduce the risk of withdrawal symptoms in the newborn (Larsen 2015).

Data collection to monitor pregnancy and infant outcomes following exposure to alprazolam is ongoing. Health care providers are encouraged to enroll patients exposed to alprazolam during pregnancy in the National Pregnancy Registry for Psychiatric Medications (1-866-961-2388).

Breastfeeding Considerations

Alprazolam is present in breast milk.

Data related to the presence of alprazolam in breast milk are available:

• Following administration of a single oral dose of alprazolam 0.5 mg to 8 patients, 6 to 28 weeks postpartum, peak breast milk concentrations of alprazolam occurred at ~1 hour and the half-life was ~14 hours; metabolites were not detected. Peak breast milk concentrations of alprazolam (3.7 ± 1.59 ng/mL) were ~60% lower than the peak maternal serum concentration. Authors of the study calculated the relative infant dose (RID) of alprazolam via breast milk to be 3% of the weight-adjusted maternal dose (Oo 1995).

• Breast milk was collected from 2 patients, 3 to 6 days postpartum, who had been taking alprazolam during pregnancy and after delivery. Breast milk was sampled 2 hours after the maternal dose, approximately when the peak maternal plasma concentration occurs. The first patient was taking alprazolam 0.8 mg/day; the peak breast milk concentration of alprazolam was 3.4 ng/mL. The second patient was taking alprazolam 2.4 mg/day, providing a peak breast milk concentration of 24.5 ng/mL. The authors of the study calculated the RID of alprazolam via breast milk, compared to the weight-adjusted maternal dose, 2 different ways: first by using the actual amount of breast milk ingested, then by using a theoretical milk intake of 150 mL/kg/day (the average amount ingested by an exclusively breastfed infant). For the first case, the RID of alprazolam was 2% (based on actual intake) compared to 3.8% (theoretical intake). For the second case, the postpartum RID of alprazolam was 7.3% (based on actual intake) compared to 9.3% (theoretical intake). The first patient also had breast milk sampled 1.5 hours after a maternal dose of 1 mg/day at the 1-month postpartum visit. Alprazolam concentrations in breast milk at this time were 5.42 ng/mL and the RID was calculated to be 5.3% (actual intake) and 4.6% (theoretical intake) (Nishimura 2021).

• In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000). However, some sources note breastfeeding should only be considered if the RID is <5% for psychotropic agents (Larsen 2015).

Drowsiness, lethargy, or weight loss in breastfeeding infants has been observed in case reports following maternal use of some benzodiazepines (Iqbal 2002). Case reports have noted drowsiness (Ito 1993) or CNS depression (Kelly 2012) in infants exposed to alprazolam while breastfeeding. Symptoms of withdrawal were described in an infant following alprazolam exposure in utero and via breast milk (Anderson 1989).

Breastfeeding during benzodiazepine therapy is not recommended due to the potential for drowsiness in the breastfeeding infant (Larsen 2015); breastfeeding during alprazolam therapy is not recommended by the manufacturer. If a benzodiazepine is needed in breastfeeding patients, use of a short-acting agent is preferred (WHO 2002).

Dietary Considerations

Orally-disintegrating tablets may contain phenylalanine.

Monitoring Parameters

Respiratory and cardiovascular status; mental alertness; assess risk for abuse, misuse, and substance use disorder.

Mechanism of Action

Short-acting benzodiazepine (Griffin 2013). Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Readily absorbed; Extended release: Slower relative to immediate release formulation resulting in a concentration that is maintained 5 to 11 hours after dosing; rate increased following night time dosing (versus morning dosing).

Duration of action: Adults: Classified as a short-acting benzodiazepine; classification based on benzodiazepines with half-life between 1 and 12 hours (Griffin 2013).

Distribution: Immediate release: Vd: 0.84 to 1.42 L/kg (Greenblatt 1993).

Protein binding: 80%; primarily to albumin.

Metabolism: Hepatic via CYP3A4; forms two active metabolites (4-hydroxyalprazolam and α-hydroxyalprazolam [about half as active as alprazolam]) and an inactive metabolite benzophenone metabolite, however, the active metabolites are unlikely to contribute to much of the pharmacologic effects because of their low concentrations and lesser potencies.

Bioavailability: Immediate release: 84% to 92% (Greenblatt 1993); Extended release: 90%.

Half-life elimination:

Adults: 11.2 hours (Immediate release range: 6.3 to 26.9 hours; Extended release range: 10.7 to 15.8 hours); Orally-disintegrating tablet: Mean: 12.5 hours (range: 7.9 to 19.2 hours).

Alcoholic liver disease: 19.7 hours (range: 5.8 to 65.3 hours).

Obesity: 21.8 hours (range: 9.9 to 40.4 hours).

Elderly: 16.3 hours (range: 9 to 26.9 hours).

Time to peak, serum:

Immediate release: 1 to 2 hours.

Extended release: Adolescents and Adults: ~9 hours, relatively steady from 4 to 12 hours (Glue 2006); decreased by 1 hour when administered at bedtime (as compared to morning administration); decreased by 33% when administered with a high-fat meal; increased by 33% when administered ≥1 hour after a high-fat meal.

Orally-disintegrating tablet: 1.5 to 2 hours; occurs ~15 minutes earlier when administered with water; increased to ~4 hours when administered with a high-fat meal.

Excretion: Urine (as unchanged drug and metabolites).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Race/ethnicity: Maximal concentrations and half-life are approximately 15% and 25% higher in Asians.

Cigarette smoking: Concentrations may be reduced by up to 50% in smokers.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Apo alpraz | Xanax;
  • (AR) Argentina: Alplax | Alprazolam Cevallo | Alprazolam denver farma | Alprazolam fabra | Alprazolam klonal | Alprazolam labsa | Alprazolam luar | Alprazolam Microsules | Alprazolam northia | Alprazolam Puntanos | Alprim | Amziax | Ansielix | Becede | Bestrol | Callpax | Calmol | Emeral | Krama | Nivelan N | Plasedan | Prenadona | Prinox | Psicosedol | Pta | Razolam | Relaxten | Retan | Rilow | Rospaz | Tensium | Tranquinal | Xanax;
  • (AT) Austria: Alprastad | Alprazolam Ratiopharm | Alprazolam-arcana | Xanor;
  • (AU) Australia: Alprax | Alprazolam-bc | Alprazolam-dp | Alprazolam-Ga | Chem mart alprazolam | Cm alprazolam | Kalma | Ralozam | Tw alprazolam | Xanax | Zamhexal;
  • (BD) Bangladesh: Alaxen | Alpam | Alprax | Alzolam | Nixalo | Serelam | Xanax | Xiotic | Xolam | Zolax | Zolium | Zolium xr;
  • (BE) Belgium: Alpratop | Alpraz | Alprazolam bexal | Alprazolam eurogenerics | Alprazolam mithra pharmaceut. | Alprazolam Mylan | Alprazolam Ratiopharm | Alprazolam sandoz | Alprazolam teva generics belg | Alprazomed | Arivics | Docalprazo | Topazolam | Xanax;
  • (BF) Burkina Faso: Alpraz | Xanax;
  • (BG) Bulgaria: Frontin | Maprazax | Sophanax | Xanax sr;
  • (BR) Brazil: Alfron | Altrox | Apraz | Constante | Frontal | Frontal xr | Teufron | Tranquinal | Zoldac;
  • (CH) Switzerland: Xanax;
  • (CI) Côte d'Ivoire: Alpraz | Stresof | Xanax;
  • (CL) Chile: Adax | Ansiopax | Grifoalpram | Prazam | Sanerva | Tricalma | Zotran;
  • (CN) China: Jia le ding;
  • (CO) Colombia: Alprasyn | Benzolam | Dixin | Nirvan | Tensivan | Tranquinal | Tricalma | Xanax;
  • (CZ) Czech Republic: Alprazolam aurovitas | Alprazolam orion | Alprox | Frontin | Helex | Neurol | Xanax;
  • (DE) Germany: Alprazolam 1 A Pharma | Alprazolam hexal | Alprazolam Ratiopharm | Alprazolam sandoz | Cassadan | Esparon | Tafil | Xanax;
  • (DO) Dominican Republic: Almir | Alplax | Alprazolam lam | Angiozil | Daclor | Duazolam | Kentium | Meprax | Nervus | Pazolan | Tafil | Tapofen | Tensivan | Tranquinal;
  • (EC) Ecuador: Adax | Alprazolam la sante | Alprazolan | Alzam | Ansiolit | Biofree | Grifoalpram | Librazolam | Tranquinal | Xanax;
  • (EE) Estonia: Alprazolam krka | Alprazolam orion | Alprazolam sandoz | Alprox | Xanax;
  • (EG) Egypt: Alpracid | Alprax | Alpraz | Anxigo | Prazolam | Prazonex | Restolam | Tibazolax | Xanax | Zolam | Zolapar;
  • (ES) Spain: Alprazolam alter | Alprazolam aurobindo | Alprazolam aurovitas | Alprazolam bayvit | Alprazolam cinfa | Alprazolam combix | Alprazolam Diasa | Alprazolam edigen | Alprazolam esteve | Alprazolam kern | Alprazolam krka | Alprazolam mabo | Alprazolam neuraxpharm | Alprazolam normon | Alprazolam Pharmagenus | Alprazolam Qualix | Alprazolam Ranbaxy | Alprazolam Ratiopharm | Alprazolam Tarbis | Alprazolam tecnigen | Trankimazin;
  • (FI) Finland: Alprazolam Alternova | Alprazolam Generics | Alprazolam krka | Alprazolam Merck NM | Alprazolam sandoz | Alprox | Xanor;
  • (FR) France: Alprazolam almus | Alprazolam alter | Alprazolam Arrow | Alprazolam Biogaran | Alprazolam cristers | Alprazolam g gam | Alprazolam gnr | Alprazolam hcs | Alprazolam irex | Alprazolam isomed | Alprazolam merck | Alprazolam Ratiopharm | Alprazolam rpg | Alprazolam sandoz | Alprazolam Teva | Alprazolam zentiva | Alprazolam zydus | Xanax;
  • (GB) United Kingdom: Xanax;
  • (GR) Greece: Alprazolam/aurobindo | Alprazolam/gerard | Antanax | Saturnil | Xanax;
  • (HK) Hong Kong: Alprax | Nalion | Vick Alprazolam | Xanax;
  • (HR) Croatia: Helex | Misar | Xanax | Xanax sr;
  • (HU) Hungary: Alprazolam orion | Alprazolam sandoz | Alprox | Apo-Alpraz | Frontin | Huma-alprazol | Xanax sr;
  • (ID) Indonesia: Actazolam | Alganax | Alprazolam OGB Mersi | Alviz | Apazol | Calmlet | Feprax | Frixitas | Grazolam | Opizolam | Xanax | Zolastin | Zypraz;
  • (IE) Ireland: Alprazolam krka | Alprox | Calmax | Gerax | Xanax;
  • (IL) Israel: Alpralid | Alprox | Apox | Xanagis | Xanax;
  • (IN) India: Aaram | Alam | Alap | Alcalm | Aleez | Alep | Algo | Alltop | Almax | Alp | Alpaz | Alpon | Alpradol | Alpram | Alpramed | Alpraquil | Alprasant | Alprastan | Alprax | Alprazone | Alprocontin | Alproenar | Alprolife | Alpronat | Alprose | Alprozam | Alrex | Alzac | Alzam | Alzex | Alzid | Alzin | Alzo | Alzokam | Alzolam | Alzolex | Alzolite | Alzomax | Alzonex | Alzopax | Alzoplex | Alzot | Anax | Ancolam | Andenax | Anxeron | Anxicalm | Anxico | Anxigon | Anxilet | Anxinil | Anxit | Anxitab | Anxorel | Anxyl | Anzilum | Anzofree | Ateez | Atrest | Balmusa | Besquil | Bio zolam | Bliz | Coolam | Copax | D.d.lam | Deproz | Dial | Eldezolam | Eureplax | Exal | Fad | Fitkul | Galprex | Halozam | Jolistar | Kaprolam | Lam | Lampose | Lazolam | Luzarn | Lypraz | Manorest | Medizolam | Meriproz | Nitril | Notence | Pacific | Pacyl | Pizolam | Plaxid | Poize | Praxal | Praz | Prazolam | Procalm | Prolam | Quiet | Razolam | Restyl | Rian | Runrest | Salirest | Shanti | Sinzolam | Sleepam | Solace | Somnia | Sowel | Stresease | Stresnil rf | Synozolam | Tagat | Tenan | Tenscure | Tensimate | Tensyl | Texidep | Texina | Tiox | Tranax | Tranisol | Trans | Tre | Trika | Troycalm | Visram | Welnorm | Xanti | Xycalm | Zallpam | Zam | Zamitol | Zecalm | Zeftra | Zenax | Zenoprax | Zocam | Zodia ds | Zolam | Zolax | Zoldac | Zolent | Zolin | Zolipax | Zoloid | Zomark | Zopax | Zopic | Zorax | Zozo;
  • (IS) Iceland: Tafil;
  • (IT) Italy: Alpravecs | Alprazig | Alprazolam Actavis | Alprazolam alter | Alprazolam aurobindo | Alprazolam Doc | Alprazolam eg | Alprazolam krka | Alprazolam Mylan | Alprazolam sandoz | Alprazolam sigma tau | Frontal | Mialin | Valeans | Xanax;
  • (JO) Jordan: Alpranax | Prazin | Xanax | Zolam | Zolaram | Zolarem;
  • (JP) Japan: Azolitan | Calmdown | Constan | Medepolin | Menbit | Solanax | Wideslow;
  • (KE) Kenya: Alzolam | Atrest | Poex | Xanax | Zolaram;
  • (KR) Korea, Republic of: Alexan | Alpram | Alpranaks | Alpranax | Alzax | Anex | Azolac | Jeil alprazolam | Sapram | Xanax | Xyren | Zacetin | Zanapam;
  • (KW) Kuwait: Apo alpraz | Xanax;
  • (LB) Lebanon: Alprox | Apo alpraz | Pazolam | Tranquinal | Xanax | Zolarem;
  • (LT) Lithuania: Alprazolam ingen | Alprazolam orion | Cassadan | Frontin | Helex | Neurol | Xanax | Zomiren;
  • (LU) Luxembourg: Alpraz | Alprazolam eg | Alprazolam Mithra | Docalprazo | Xanax;
  • (LV) Latvia: Alprazolam orion | Alprazolams | Alprox | Frontin | Helex | Neurol | Xanax;
  • (MA) Morocco: Alpraz | Alprazolam win | Xanax;
  • (MX) Mexico: Alamsid | Alprazolam gi prot | Alzam | Amsotazona | Farmapram | Furgilim | Neupax | Noxeprom | Pisalpra | Suntazun | Tafil | Tafil ap | Tazun | Torantsita | Xanax | Zamoprax;
  • (MY) Malaysia: Alpraline | Alpranax | Apo-Alpraz | Asolan | Inzolam | Prazovex | Xanapam | Xanax | Zovex;
  • (NL) Netherlands: Alprazolam Actavis | Alprazolam dum | Alprazolam kwk | Alprazolam Ratiopharm | Xanax;
  • (NO) Norway: Alprozolam | Xanax | Xanor;
  • (NZ) New Zealand: Arrow Alprazolam | Xanax;
  • (PE) Peru: Alpaz | Grifoalpram | Labox | Laboxut | Pazolam | Relaxol | Serenil | Tranquinal | Tricalma | Xanax | Zopral;
  • (PH) Philippines: Altraxic | Altrox | Axal | Xanor | Xanor xr | Zolgen;
  • (PK) Pakistan: Aloram | Alp | Alpax | Alpram | Alprazom | Alprox | Altanid | Alz | Alzolam | Anpra | Anrid | Anxnil | Anzilum | Arnax | Axal | Azolam | Azolex | Bizolam | Brnax | Crozam | Enzo | Hilaxin | Jibrone | Lampro | Lapranx | Lydia | M Zolam | Mazolam | Medilap | Nax | Neram | Nervin | Neuxam | Noxalam | Onax | Pinix | Pralzo | Pranax | Praz | Prazolam | Prolam | Prozam | Razlam | Rosam | Shenlax | Syms | Tasolam | Xanax | Xylepam | Zanac | Zenith | Zolarem;
  • (PL) Poland: Afobam | Alpragen | Alprazolam aurovitas | Alprazomerck | Alprox | Neurol | Tafil | Xanax | Zomiren;
  • (PR) Puerto Rico: Alprazolam er | Niravam | Xanax;
  • (PT) Portugal: Alprazolam labesfal | Alprazolam Merck genericos | Alprazolam Ratiopharm | Alprazolam sandoz | Alprazolam tad | Alprazolam vitoria | Alprazolam Wynn | Alpronax | Pazolam | Prazam | Unilan | Xanax;
  • (PY) Paraguay: Aceprax | Almosedan | Alplax | Alpranest | Alprazolam incomex | Alprazolam la sante | Alprazolam natrodale | Alprazolam pasteur | Alprazolam phi | Alprazolam polimed | Alzolam | Grifoalpran | Moderane | Moderex | Moderex retard | Neurozepan md | Psicozolam | Sedaler | Sedatival | Sedipral | Sedo aportil | Sedocalcio aportil | Sensitral | Todotranqui | Tranquinal | Tresanil | Tri neurin | Tricalma;
  • (QA) Qatar: Apo-Alpraz | Xanax;
  • (RO) Romania: Alprazolam atb | Alprazolam lph | Alprox | Frontin | Helex | Prazolex | Xanax | Zolarem;
  • (RU) Russian Federation: Alzolam | Cassadan | Helex | Neurol | Xanax | Zoldac | Zolomaks;
  • (SA) Saudi Arabia: Xanax | Zolam;
  • (SE) Sweden: Alpralid | Alprazolam Alternova | Alprazolam krka | Alprazolam Merck NM | Alprazolam Mylan | Alprazolam orion | Alprazolam sandoz | Alprazolam Stada | Xanor;
  • (SG) Singapore: Alzolam | Apo-Alpraz | Xanax | Zacetin;
  • (SI) Slovenia: Helex | Maprazax | Xanax;
  • (SK) Slovakia: Alprazolam orion | Frontin | Helex | Neurol | Xanax;
  • (TH) Thailand: Alcelam | Alnax | Alpramed | Anax | Anpress | Dizolam | Farzolam | Inzolam | Manex | Marzolam | Mitranax | Moxinax | Pharnax | Prazol | Siampraxol | Xanacine | Xanax | Xiemed | Zolam;
  • (TN) Tunisia: Prazine | Xanax;
  • (TR) Turkey: Ansiox | Stabina | Xanax;
  • (TW) Taiwan: Alpragin | Alpraline | Alprox | Amprazo | Aprazo | Gendergin | Kalma | Kinax | Vanipen | Xanax;
  • (UA) Ukraine: Xanax;
  • (UG) Uganda: Alprazec;
  • (UY) Uruguay: Aceprax | Akrozolam | Alplacin | Alplacin digest | Alplacin xr | Ansionil | Kentium | Ondil | Tranquinal | Tresanil;
  • (VE) Venezuela, Bolivarian Republic of: Abaxon | Alpram | Alpramack | Ansilan | Caplam | Danox | Logat | Tafil | Tagut;
  • (ZA) South Africa: Adco alzam | Alzam | Apo-alprazolam | Azor | Cpl alliance alprazolam | Merck-alprazolam | Novapraz xr | Panix | Xanolam | Xanor | Zopax;
  • (ZM) Zambia: Manorest
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Albrecht B, Staiger PK, Hall K, Kambouropoulos N, Best D. Motivational drive and alprazolam misuse: A recipe for aggression? Psychiatry Res. 2016;240:381-389. doi:10.1016/j.psychres.2016.04.040 [PubMed 27138835]
  3. Allison C, Pratt JA. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Ther. 2003;98(2):171-195. doi:10.1016/s0163-7258(03)00029-9 [PubMed 12725868]
  4. Alprazolam Intensol oral solution (concentrate) [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA; January 2023.
  5. Alprazolam orally disintegrating tablets [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; November 2022.
  6. Alprazolam orally disintegrating tablets [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; April 2023.
  7. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin No. 92: Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910 [PubMed 18378767]
  8. Anderson PO, McGuire GG. Neonatal alprazolam withdrawal--possible effects of breast feeding. DICP. 1989;23(7-8):614. [PubMed 2763587]
  9. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi:10.1002/cpt.377 [PubMed 27060684]
  10. Authier N, Balayssac D, Sautereau M, et al. Benzodiazepine dependence: focus on withdrawal syndrome. Ann Pharm Fr. 2009;67(6):408-413. doi:10.1016/j.pharma.2009.07.001 [PubMed 19900604]
  11. Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. World J Biol Psychiatry. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295 [PubMed 35900161]
  12. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry. 2013;35(1):3-8. doi:10.1016/j.genhosppsych.2012.09.003 [PubMed 23044244]
  13. Bernstein GA, Garfinkel BD, Borchardt CM. Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry. 1990;29(5):773-781. doi:10.1097/00004583-199009000-00016 [PubMed 2228932]
  14. Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). Otolaryngol Head Neck Surg. 2017;156(suppl 3):S1‐S47. doi:10.1177/0194599816689667 [PubMed 28248609]
  15. Bond AJ, Curran HV, Bruce MS, O'Sullivan G, Shine P. Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. J Affect Disord. 1995;35(3):117-123. doi:10.1016/0165-0327(95)00053-4 [PubMed 8749839]
  16. Bond AJ. Drug-induced behavioural disinhibition: Incidence, mechanisms and therapeutic implications. CNS Drugs. 1998;9(1):41-57. [PubMed Bond.1]
  17. Bond AJ, Silveira JC. The combination of alprazolam and alcohol on behavioral aggression. J Stud Alcohol Suppl. 1993;11:30-39. doi:10.15288/jsas.1993.s11.30 [PubMed 8410962]
  18. Bond A, Lader M. Differential effects of oxazepam and lorazepam on aggressive responding. Psychopharmacology (Berl). 1988;95(3):369-373. doi:10.1007/BF00181949 [PubMed 3137624]
  19. Busto UE, Kaplan HL, Wright CE, et al. A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam. J Clin Psychopharmacol. 2000;20(6):628-635. doi:10.1097/00004714-200012000-00008 [PubMed 11106134]
  20. Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986;315(14):854-859. doi:10.1056/NEJM198610023151403 [PubMed 3092053]
  21. Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 1998 Apr;26(4):676-684. doi:10.1097/00003246-199804000-00015 [PubMed 9559604]
  22. Cassano GB, Toni C, Petracca A, et al. Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. Eur Neuropsychopharmacol. 1994;4(1):47-53. doi:10.1016/0924-977x(94)90314-x [PubMed 8204996]
  23. Chen VC, Wu SI, Lin CF, Lu ML, Chen YL, Stewart R. Association of prenatal exposure to benzodiazepines with development of autism spectrum and attention-deficit/hyperactivity disorders. JAMA Netw Open. 2022;5(11):e2243282. doi:10.1001/jamanetworkopen.2022.43282 [PubMed 36413366]
  24. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;(65 Suppl 5):7-12. [PubMed 15078112]
  25. Chowdhury ZS, Morshed MM, Shahriar M, Bhuiyan MA, Islam SM, Bin Sayeed MS. The effect of chronic alprazolam intake on memory, attention, and psychomotor performance in healthy human male volunteers. Behav Neurol. 2016;2016:3730940. doi:10.1155/2016/3730940 [PubMed 27462136]
  26. Choy Y. Acute procedural anxiety and specific phobia of clinical procedures in adults: Treatment overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 6, 2020.
  27. Commander M, Green SH, Prendergast M. Behavioural disturbances in children treated with clonazepam. Dev Med Child Neurol. 1991;33(4):362-363. doi:10.1111/j.1469-8749.1991.tb14889.x [PubMed 1904374]
  28. Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020;89(5):283-306. doi:10.1159/000506868 [PubMed 32259826]
  29. Craske M, Bystritsky A. Generalized anxiety disorder in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 19, 2022.
  30. Curran HV. Benzodiazepines, memory and mood: a review. Psychopharmacology (Berl). 1991;105(1):1-8. doi: 10.1007/BF02316856 [PubMed 1684055]
  31. Curran HV, Bond A, O'Sullivan G, et al. Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. Psychol Med. 1994;24(4):969-976. doi:10.1017/s0033291700029056 [PubMed 7892364]
  32. Dawson J, Boyle J, Stanley N, Johnsen S, Hindmarch I, Skene DJ. Benzodiazepine-induced reduction in activity mirrors decrements in cognitive and psychomotor performance. Hum Psychopharmacol. 2008;23(7):605-613. doi:10.1002/hup.961 [PubMed 18570226]
  33. De Witte JL, Alegret C, Sessler DI, Cammu G. Preoperative alprazolam reduces anxiety in ambulatory surgery patients: a comparison with oral midazolam. Anesth Analg. 2002;95(6):1601-1606. [PubMed 12456424]
  34. Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Sáez de Adana E, et al. Relationship between the use of benzodiazepines and falls in older adults: a systematic review. Maturitas. 2017;101:17-22. doi:10.1016/j.maturitas.2017.04.002 [PubMed 28539164]
  35. Dickinson B, Rush PA, Radcliffe AB. Alprazolam use and dependence. A retrospective analysis of 30 cases of withdrawal. West J Med. 1990;152(5):604-608. [PubMed 2349800]
  36. Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs. 2008;22(12):1021-1036. doi:10.2165/0023210-200822120-00005. [PubMed 18998740]
  37. Ellinwood EH Jr, Nikaido AM, Gupta SK, Heatherly DG, Hege S. Comparison of the relationship between structure and CNS effects for lorazepam, clonazepam and alprazolam. J Psychopharmacol. 1993;7(1 Suppl):24-32. doi:10.1177/0269881193007001051 [PubMed 22290367]
  38. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  39. Fleishaker JC, Garzone PD, Chambers JH, Sirocco K, Weingartner H. Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects. Psychopharmacology (Berl). 1995;120(2):169-176. doi:10.1007/BF02246190 [PubMed 7480549]
  40. Freeman MP, Góez-Mogollón L, McInerney KA, et al. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders. Gen Hosp Psychiatry. 2018;53:73-79. doi:10.1016/j.genhosppsych.2018.05.010 [PubMed 29958100]
  41. Furman JM, Barton JJS. Treatment of vertigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 28, 2022.
  42. García-Algar O, López-Vílchez MA, Martín I, et al. Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Clin Toxicol (Phila). 2007;45(3):295-298. doi:10.1080/15563650601072191 [PubMed 17453885]
  43. Glue P, Fang A, Gandelman K, et al, “Pharmacokinetics of an Extended Release Formulation of Alprazolam (Xanax XR) in Healthy Normal Adolescent and Adult Volunteers,” Am J Ther, 2006, 13(5):418-22. [PubMed 16988537]
  44. Greenberg DB, Surman OS, Clarke J, Baer L. Alprazolam for phobic nausea and vomiting related to cancer chemotherapy. Cancer Treat Rep. 1987;71(5):549‐550. [PubMed 3567983]
  45. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet.1993;24(6):453-471. [PubMed 8513649]
  46. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214-223. [PubMed 23789008]
  47. Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. J Clin Psychiatry. 2019;80(4):18r12412. doi:10.4088/JCP.18r12412 [PubMed 31294935]
  48. Guina J, Merrill B. Benzodiazepines I: upping the care on downers: the evidence of risks, benefits and alternatives. J Clin Med. 2018;7(2):17. doi:10.3390/jcm7020017 [PubMed 29385731]
  49. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240‐3261. doi:10.1200/JCO.2017.74.4789 [PubMed 28759346]
  50. Iqbal MM, Sobhan T, Ryals T, et al. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002;53(1):39-49. [PubMed 11773648]
  51. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208 [PubMed 10891521]
  52. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168(5):1393-1399. [PubMed 8498418]
  53. Jennum P, Baandrup L, Ibsen R, et al. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. Eur Neuropsychopharmacol. 2015;25(11):1906-1913. doi: 10.1016/j.euroneuro.2015.08.014. [PubMed 26342397]
  54. Judd FK, Norman TR, Marriott PF, Burrows GD. A case of alprazolam-related hepatitis. Am J Psychiatry. 1986;143(3):388-389. doi:10.1176/ajp.143.3.388b [PubMed 2869702]
  55. Juergens SM, Morse RM. Alprazolam dependence in seven patients. Am J Psychiatry. 1988;145(5):625-627. doi:10.1176/ajp.145.5.625 [PubMed 3258735]
  56. Kalachnik JE, Hanzel TE, Sevenich R, Harder SR. Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. Am J Ment Retard. 2002;107(5):376-410. doi:10.1352/0895-8017(2002)107<0376:BBSERA>2.0.CO;2 [PubMed 12186578]
  57. Kanwar AJ, Gupta R, Das Mehta S, Kaur S. Photosensitivity due to alprazolam. Dermatologica. 1990;181(1):75. [PubMed 2394310]
  58. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1 [PubMed 25081580]
  59. Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. J Pediatr. 2012;161(3):448-451. [PubMed 22504099]
  60. Kirkpatrick D, Smith T, Kerfeld M, Ramsdell T, Sadiq H, Sharma A. Paradoxical reaction to alprazolam in an elderly woman with a history of anxiety, mood disorders, and hypothyroidism. Case Rep Psychiatry. 2016;2016:6748947. doi:10.1155/2016/6748947 [PubMed 27092285]
  61. Kumar R, Mac DS, Gabrielli WF Jr, Goodwin DW. Anxiolytics and memory: a comparison of lorazepam and alprazolam. J Clin Psychiatry. 1987;48(4):158-160. [PubMed 3558328]
  62. Lader M. Benzodiazepines revisited--will we ever learn? Addiction. 2011;106(12):2086‐2109. doi:10.1111/j.1360-0443.2011.03563.x [PubMed 21714826]
  63. Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1-28. [PubMed 26344706]
  64. Lee H, Koh JW, Kim YA, et al. Pregnancy and neonatal outcomes after exposure to alprazolam in pregnancy. Front Pharmacol. 2022;13:854562. doi:10.3389/fphar.2022.854562 [PubMed 35548333]
  65. Leufkens TR, Vermeeren A, Smink BE, van Ruitenbeek P, Ramaekers JG. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology (Berl). 2007;191(4):951-959. doi:10.1007/s00213-006-0669-8 [PubMed 17219217]
  66. Linnoila M, Stapleton JM, Lister R, et al. Effects of single doses of alprazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. Eur J Clin Pharmacol. 1990;39(1):21-28. doi:10.1007/BF02657051 [PubMed 2276384]
  67. Little JD, Taghavi EH. Disinhibition after lorazepam augmentation of antipsychotic medication. Am J Psychiatry. 1991;148(8):1099-1100. doi:10.1176/ajp.148.8.1099a [PubMed 1677237]
  68. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy. 2004;24(9):1177-1185. [PubMed 15460178]
  69. Mazzilli R, Curto M, De Bernardini D, et al. Psychotropic drugs levels in seminal fluid: a new therapeutic drug monitoring analysis? Front Endocrinol (Lausanne). 2021;12:620936. doi:10.3389/fendo.2021.620936 [PubMed 33776918]
  70. McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31(5):519-552. doi:10.1177/0269881117699361 [PubMed 28440103]
  71. Mejo SL. Anterograde amnesia linked to benzodiazepines. Nurse Pract. 1992;17(10):44, 49-50. doi:10.1097/00006205-199210000-00013 [PubMed 1357612]
  72. Mellman TA, Uhde TW. Withdrawal syndrome with gradual tapering of alprazolam. Am J Psychiatry. 1986;143(11):1464-1466. doi:10.1176/ajp.143.11.1464 [PubMed 3535544]
  73. Mohns EB. Discontinuation and withdrawal problems of alprazolam. West J Med. 1989;151(3):312. [PubMed 18750636]
  74. Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol. 1999;6(2):69-83. [PubMed 10519733]
  75. Niravam orally disintegrating tablets (alprazolam) [prescribing information]. Philadelphia, PA: Azur Pharma, Inc; January 2011.
  76. Nishimura A, Furugen A, Umazume T, et al. Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose. Breastfeed Med. 2021;16(5):424-431. doi:10.1089/bfm.2020.0259 [PubMed 33449825]
  77. Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: a population-based cohort study in South Korea. PLoS Med. 2022;19(3):e1003945. doi:10.1371/journal.pmed.1003945 [PubMed 35235572]
  78. Nutt DJ. Pharmacological mechanisms of benzodiazepine withdrawal. J Psychiatr Res. 1990;24(Suppl 2):105-110. doi:10.1016/0022-3956(90)90041-n [PubMed 1980689]
  79. Ochs HR, Greenblatt DJ, Labedzki L, Smith RB. Alprazolam kinetics in patients with renal insufficiency. J Clin Psychopharmacol. 1986;6(5):292-294. [PubMed 3771810]
  80. Oldham MA, Desan PH. Alcohol and sedative-hypnotic withdrawal catatonia: two case reports, systematic literature review, and suggestion of a potential relationship with alcohol withdrawal delirium. Psychosomatics. 2016;57(3):246-255. doi:10.1016/j.psym.2015.12.007 [PubMed 26949118]
  81. Oo CY, Kuhn RJ, Desai N, et al. Pharmacokinetics in Lactating Women: Prediction of Alprazolam Transfer Into Milk. Br J Clin Pharmacol. 1995;40(3):231-236. [PubMed 8527284]
  82. O'Sullivan GH, Noshirvani H, Başoğlu M, et al. Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder. Br J Psychiatry. 1994;165(1):79-86. doi:10.1192/bjp.165.1.79 [PubMed 7802851]
  83. Park TW. Benzodiazepine use disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 12, 2022.
  84. Pecknold JC. Discontinuation reactions to alprazolam in panic disorder. J Psychiatr Res. 1993;27(Suppl 1):155-170. doi:10.1016/0022-3956(93)90025-w [PubMed 8145176]
  85. Petrić D, Peitl MV, Peitl V. High doses alprazolam induced amenorrhoea and galactorrhoea. Psychiatr Danub. 2011;23:123-124. [PubMed 21448116]
  86. Pfefferbaum B, Overall JE, Boren HA, et al, “Alprazolam in the Treatment of Anticipatory and Acute Situational Anxiety in Children With Cancer,” J Am Acad Child Adolesc Psychiatry, 1987, 26(4):532-5. [PubMed 3654506]
  87. Radojčić MR, El Marroun H, Miljković B, et al. Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: a population-based cohort study. Neurotoxicol Teratol. 2017;61:58-65. doi:10.1016/j.ntt.2017.02.005 [PubMed 28259732]
  88. Rapaport M, Braff DL. Alprazolam and hostility. Am J Psychiatry. 1985;142(1):146. doi:10.1176/ajp.142.1.146a [PubMed 2857070]
  89. Razavi D, Delvaux N, Farvacques C, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol. 1993;11(7):1384‐1390. doi:10.1200/JCO.1993.11.7.1384 [PubMed 8315437]
  90. Reddy MSS, Achary U, Harbishettar V, Sivakumar PT, Varghese M. Paradoxical reaction to benzodiazepines in elderly - case series. Asian J Psychiatr. 2018;35:8-10. doi:10.1016/j.ajp.2018.04.037 [PubMed 29723722]
  91. Refer to manufacturer's labeling.
  92. Roth T, Roehrs T, Wittig R, Zorick F. Benzodiazepines and memory. Br J Clin Pharmacol. 1984;18(Suppl 1):45S-49S. doi:10.1111/j.1365-2125.1984.tb02581.x [PubMed 6151849]
  93. Rothschild AJ, Shindul-Rothschild JA, Viguera A, Murray M, Brewster S. Comparison of the frequency of behavioral disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. J Clin Psychopharmacol. 2000;20(1):7-11. doi:10.1097/00004714-200002000-00003 [PubMed 10653202]
  94. Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. Int J Geriatr Psychiatry. 2018;33(4):583-590. doi: 10.1002/gps.4821. [PubMed 29143367]
  95. Scavone JM, Greenblatt DJ, Goddard JE, Friedman H, Harmatz JS, Shader RI. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state. Eur J Clin Pharmacol. 1992;42(4):439-443. [PubMed 1516609]
  96. Scavone JM, Greenblatt DJ, Shader RI. Alprazolam kinetics following sublingual and oral administration. J Clin Psychopharmacol. 1987;7(5):332-334. [PubMed 3680603]
  97. Schmith VD, Piraino B, Smith RB, Kroboth PD. Alprazolam in end-stage renal disease: I. Pharmacokinetics. J Clin Pharmacol. 1991;31(6):571-579. doi:10.1002/j.1552-4604.1991.tb03740.x [PubMed 1880224]
  98. Schmith VD, Piraino B, Smith RB, Kroboth PD. Alprazolam in end-stage renal disease. II. Pharmacodynamics. Clin Pharmacol Ther. 1992;51(5):533-540. doi:10.1038/clpt.1992.59 [PubMed 1587068]
  99. Seidel WF, Cohen SA, Wilson L, Dement WC. Effects of alprazolam and diazepam on the daytime sleepiness of non-anxious subjects. Psychopharmacology (Berl). 1985;87(2):194-197. doi:10.1007/BF00431806 [PubMed 3931145]
  100. Shavakhi A, Soleiman S, Gholamrezaei A, et al. Premedication with sublingual or oral alprazolam in adults undergoing diagnostic upper gastrointestinal endoscopy. Endoscopy. 2014;46(8):633‐639. doi:10.1055/s-0034-1377305 [PubMed 24977401]
  101. Sheehan MF, Sheehan DV, Torres A, Coppola A, Francis E. Snorting benzodiazepines. Am J Drug Alcohol Abuse. 1991;17(4):457-468. doi:10.3109/00952999109001605 [PubMed 1684083]
  102. Shioiri T, Kita N, Takahashi S. Two cases of alprazolam-induced hyperprolactinemia in patients with panic disorder. Int Clin Psychopharmacol. 1996;11(2):149-152. [PubMed 8803653]
  103. Short TG, Forrest P, Galletly DC. Paradoxical reactions to benzodiazepines--a genetically determined phenomenon? Anaesth Intensive Care. 1987;15(3):330-331. doi:10.1177/0310057X8701500314 [PubMed 3661967]
  104. Simeon JG, Ferguson HB, Knott V, et al, “Clinical, Cognitive, and Neurophysiological Effects of Alprazolam in Children and Adolescents With Overanxious and Avoidant Disorders,” J Am Acad Child Adolesc Psychiatry, 1992, 31(1):29-33. [PubMed 1537778]
  105. Smith RB, Kroboth PD. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology (Berl). 1987;93(1):105-112. doi: 10.1007/BF02439595 [PubMed 3114808]
  106. Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology (Berl). 1984;84(4):452-456. doi:10.1007/BF00431449 [PubMed 6152055]
  107. Stein MB, Goin MK, Pollack MH, et al; Work Group on Panic Disorder; Steering Committee on Practice Guidelines. American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder. 2nd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009. Accessed May 28, 2020. [PubMed Stein.1]
  108. Sundbakk LM, Gran JM, Wood ME, Handal M, Skurtveit S, Nordeng H. Association of prenatal exposure to benzodiazepines and z-hypnotics with risk of attention-deficit/hyperactivity disorder in childhood. JAMA Netw Open. 2022;5(12):e2246889. doi:10.1001/jamanetworkopen.2022.46889 [PubMed 36520439]
  109. Sylvestre MP, Abrahamowicz M, Čapek R, Tamblyn R. Assessing the cumulative effects of exposure to selected benzodiazepines on the risk of fall-related injuries in the elderly. Int Psychogeriatr. 2012;24(4):577-586. doi:10.1017/S1041610211002031 [PubMed 22059800]
  110. Szpunar MJ, Freeman MP, Kobylski LA, et al. Risk of major malformations in infants after first-trimester exposure to benzodiazepines: results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. Depress Anxiety. 2022;39(12):751-759. doi:10.1002/da.23280 [PubMed 35909254]
  111. Tan KR, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 2011;34(4):188-197. doi:10.1016/j.tins.2011.01.004 [PubMed 21353710]
  112. Tinker SC, Reefhuis J, Bitsko RH, et al; National Birth Defects Prevention Study. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. Birth Defects Res. 2019;111(10):613-620. doi:10.1002/bdr2.1497 [PubMed 30891943]
  113. Tsuda M, Shimizu N, Suzuki T. Contribution of glutamate receptors to benzodiazepine withdrawal signs. Jpn J Pharmacol. 1999;81(1):1-6. doi:10.1254/jjp.81.1 [PubMed 10580363]
  114. US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal.pdf. Updated June 2017. Accessed March 9, 2020.
  115. US Department of Veterans Affairs/US Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf. Published August 2021. Accessed May 12, 2022.
  116. van Laar M, Volkerts E, Verbaten M. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology (Berl). 2001;154(2):189-197. doi:10.1007/s002130000633 [PubMed 11314681]
  117. Van Sickle BJ, Xiang K, Tietz EI. Transient plasticity of hippocampal CA1 neuron glutamate receptors contributes to benzodiazepine withdrawal-anxiety. Neuropsychopharmacology. 2004;29(11):1994-2006. doi:10.1038/sj.npp.1300531 [PubMed 15266351]
  118. Verster JC, Volkerts ER. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev. 2004;10(1):45-76. doi:10.1111/j.1527-3458.2004.tb00003.x [PubMed 14978513]
  119. Vicente Ferreira Naves P, Calderaro M, Caboclo LO. De novo myoclonic status epilepticus after benzodiazepine withdrawal. Clin Neuropharmacol. 2018;41(4):142-144. doi:10.1097/WNF.0000000000000283 [PubMed 29851670]
  120. Vinkers CH, Olivier B. Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective (A) Receptor Modulators? Adv Pharmacol Sci. 2012;2012:416864. [PubMed 22536226]
  121. Wang X, Zhang T, Ekheden I, et al. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: a systematic review. Neurosci Biobehav Rev. 2022;137:104647. doi:10.1016/j.neubiorev.2022.104647 [PubMed 35367514]
  122. Warner MD, Peabody CA, Boutros NN, Whiteford HA. Alprazolam and withdrawal seizures. J Nerv Ment Dis. 1990;178(3):208-209. doi:10.1097/00005053-199003000-00010 [PubMed 2307974]
  123. Wikner BN, Stiller CO, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(11):1203-1210. [PubMed 17894421]
  124. Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. J Psychopharmacol. 2019;33(8):923-947. doi:10.1177/0269881119855343 [PubMed 31271339]
  125. Wolf B, Griffiths RR. Physical dependence on benzodiazepines: differences within the class. Drug Alcohol Depend. 1991;29(2):153-156. doi:10.1016/0376-8716(91)90044-y [PubMed 1686752]
  126. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.
  127. Xanax concentrate (alprazolam) [prescribing information]. Eatontown, NJ: West-Ward Phamaceuticals Corp; June 2016.
  128. Xanax (alprazolam) [prescribing information]. New York, NY: Pharmacia and Upjohn Co; January 2023.
  129. Xanax and Xanax TS (alprazolam) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; April 2023.
  130. Xanax XR (alprazolam) [prescribing information]. New York, NY: Pharmacia and Upjohn Co; January 2023.
Topic 8453 Version 661.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟